Eltrombopag 12.5 mg Tablet bulk supplier for pharma manufacturers

Eltrombopag 12.5 Mg Tablet Suppliers & Bulk Manufacturers

Available Forms: Tablets & Oral suspension

Available Strengths: Tablet: 25 mg, 50 mg, 75 mg; Suspension: 12.5 mg/5 mL

Reference Brands: Promacta® (US & EU); Revolade®(EU)

Category: Hepatitis

Eltrombopag Tablets (Promacta® / Revolade® generic) are oral TPO receptor agonists for ITP, aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg strengths. EU-GMP/USFDA compliant, ideal for B2B supply, tenders, and licensing with full CTD support.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Eltrombopag Tablets (Promacta® / Revolade® generic) are thrombopoietin receptor agonists indicated for chronic ITP, severe aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg oral tablet strengths, the product is manufactured under EU-GMP and USFDA-compliant facilities. Offered for B2B supply, hospital tenders, and licensing deals, with full CTD dossiers, bioequivalence studies, and regulatory support. Eltrombopag is a key addition for companies supplying hematology and oncology portfolios in regulated and semi-regulated markets, supporting global access to thrombopoiesis-stimulating therapies.

Eltrombopag 12.5 Mg Tablet — third party manufacturing & bulk supply

Eltrombopag 12.5 Mg Tablet is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Eltrombopag 12.5 Mg Tablet is supplied as Tablets & Oral suspension — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Eltrombopag 12.5 Mg Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Eltrombopag 12.5 Mg Tablet →

Back to Listing

Frequently Asked Questions

Eltrombopag choline is used to treat thrombocytopenia by increasing platelet production. It is commonly prescribed for chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C.

Eltrombopag choline is a synthetic small-molecule thrombopoietin receptor agonist formulated as a choline salt for oral administration.

Eltrombopag choline is marketed under the trade names Promacta in the USA and Revolade in the EU and UK.

Eltrombopag choline products are manufactured by multiple pharmaceutical companies, including the original innovator and licensed generic manufacturers, depending on the market.

The generic name is eltrombopag choline.

The brand names are Promacta in the USA and Revolade in the EU and UK.

Eltrombopag choline formulations are manufactured in various countries including the USA, EU, and India, depending on the approved manufacturer and regulatory authorizations.